Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.32 |
| ▸ | KRAS | P01116 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052504 | 0.90 | ABL1 (0.35) | ABL1BCRMAPTSMN1; SMN2CYP8B1 | |
| SCHEMBL21050677 | 0.88 | ABL1 (0.36) | ABL1BCRCYP8B1PDGFRBKRAS | |
| SCHEMBL21050918 | 0.88 | ABL1 (0.36) | ABL1BCRCYP8B1PDGFRBKRAS | |
| SCHEMBL21050676 | 0.88 | ABL1 (0.36) | ABL1BCRCYP8B1PDGFRBKRAS | |
| SCHEMBL21050764 | 0.88 | ABL1 (0.36) | ABL1BCRCYP8B1PDGFRBKRAS | |
| SCHEMBL21050820 | 0.86 | MAPT (0.37) | ABL1BCRMAPTGAASMN1; SMN2 | |
| SCHEMBL21050944 | 0.84 | ABL1 (0.36) | ABL1BCRCYP8B1PDGFRBKRAS | |
| SCHEMBL21050902 | 0.83 | MAPT (0.35) | ABL1BCRMAPTGAASMN1; SMN2 | |
| SCHEMBL21050943 | 0.83 | MAPT (0.36) | ABL1BCRMAPTGAASMN1; SMN2 | |
| SCHEMBL21050906 | 0.80 | MAPT (0.37) | ABL1BCRMAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | ABL1 84/4885BCR 1121/4885MAPT 2445/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | ABL1 84/4885BCR 1121/4885MAPT 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.